Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in October

Coya Therapeutics, Inc. (NASDAQ:COYA) saw a significant increase in short interest in October. As of October 15th, there was short interest totalling 186,100 shares, an increase of 6.3% from the September 30th total of 175,000 shares. Based on an average daily trading volume, of 50,700 shares, the short-interest ratio is presently 3.7 days. Approximately 1.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of research firms recently weighed in on COYA. HC Wainwright started coverage on Coya Therapeutics in a report on Monday, September 16th. They issued a “buy” rating and a $18.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday.

Coya Therapeutics Price Performance

Coya Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $7.12. 63,998 shares of the company were exchanged, compared to its average volume of 71,850. The company has a market capitalization of $108.37 million, a P/E ratio of -10.00 and a beta of 0.58. The business’s 50 day simple moving average is $6.89 and its two-hundred day simple moving average is $7.10. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $3.43 million for the quarter. Equities research analysts predict that Coya Therapeutics will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the last quarter. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth $61,000. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics in the 2nd quarter worth $101,000. Finally, GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics in the third quarter valued at $169,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.